TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03116789

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: Two capsules for daily

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotics
Description: Two capsules for daily
Study: NCT00243477

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg or placebo once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram 10mg or placebo once a day
Study: NCT02227420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anakinra 100mg s.c. x 5
Study: NCT00142207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent preventive treatment:sulphadoxine-pyrimethamine
Description: Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent preventive treatment:sulphadoxine-pyrimethamine
Description: Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insecticide-treated mosquito bed net
Description: Insecticide-treated mosquito bed net

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insecticide-treated mosquito bed net
Description: Insecticide-treated mosquito bed net
Study: NCT00777439

Intervention type: DRUG
Group type: OTHER
Intervention: Domperidone
Description: 10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
Study: NCT01208376

Intervention type: OTHER
Intervention: Fibroscan
Description: Fibroscan and Serum Fibrose-marker

Intervention type: OTHER
Intervention: Fibroscan
Description: Fibroscan and Serum Fibrose-marker
Study: NCT05811000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM012 Placebo
Description: PM012 tablet placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM012 Placebo
Description: PM012 tablet placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Aricept 5 mg (donepezil hydrochloride) drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Aricept 5 mg (donepezil hydrochloride) placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Aricept 5 mg (donepezil hydrochloride) placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil placebo
Description: Aricept 5 mg (donepezil hydrochloride) placebo
Study: NCT01233284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide 2.5µg once daily
Description: Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tiotropium matching Placebo once daily
Description: Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide high dose once daily
Description: Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium bromide 1.25µg once daily
Description: IMP
Study: NCT02974764

Intervention type: OTHER
Intervention: No intervention/exposures

Intervention type: OTHER
Intervention: No intervention/exposures

Intervention type: OTHER
Intervention: No intervention/exposures
Study: NCT01287403

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esterase wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esterase wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Esterase wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esterase wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Esterase wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.
Study: NCT03928821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121
Description: 20 mg/kg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGT121
Description: 20 mg/kg administered intravenously
Study: NCT01287403

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid whole grain wheat flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid wholegrain barley flour
Description: A treated cereal flour mixed with milk.
Study: NCT04500925

Intervention type: PROCEDURE
Intervention: UNILATERAL THYROIDECTOMY

Intervention type: PROCEDURE
Intervention: UNILATERAL THYROIDECTOMY
Study: NCT03902158

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: The patient will wear virtual reality glasses during anesthesia
Study: NCT03928821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400
Description: 20 mg/kg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PGDM1400
Description: 20 mg/kg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10-1074
Description: 20 mg/kg administered intravenously
Study: NCT03902158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Distraction techniques
Description: The patient will undergo distraction techniques
Study: NCT03987165

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Music therapy will be conducted once daily using a Song of Kin, a familiar song used to lull the infant to sleep. If no Song of Kin is provided, Twinkle Twinkle Little Star will be the default lullaby.
Study: NCT02028182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lyral®
Description: Alergen panel containing ascending doses of Lyral (0.10 mg/cm\^2, 0.20 mg/cm\^2 and 0.40 mg/cm\^2) and negative control
Study: NCT02198040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: * 5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.~* 15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.~* 15 minutes. Passive muscle stretching (within the limits of mobility).~* 15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.~* 10 minutes. Local cryotherapy with ice bag and protection between it and the skin
Study: NCT03928821

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 20 mg/kg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 20 mg/kg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 20 mg/kg administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: 20 mg/kg administered intravenously
Study: NCT02935478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embospheres Microspheres
Description: Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
Study: NCT03612388

Intervention type: PROCEDURE
Intervention: use of a cardioplegic formula in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation
Description: use of a novel cardioplegic formula with MPS® (Myocardial protection system) versus Cardioplexol ® (colloid solution with Procaine, magnesium and potassium) in isolated CABG (coronary artery bypass grafting) using MiECC (Minimal extracorporeal circulation system).
Study: NCT03760809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5μg／kg
Description: Group A received dexmedetomidine 0.5μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1μg／kg
Description: Group B received dexmedetomidine 1μg／kg (diluted to 100ml，influded in 5 mins at the beginning of the surgery) and hydromophine 0.03 mg／kg as a bolus.
Study: NCT04518540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lipoic acid group
Description: The patients will take lipoic acid for 6 course, the first course of treatment is 14 days with 14 days of rest, and the following course is the first for 10 days, with 14 days interval.The patients will use 600mg domestic lipoic acid in 250ml normal saline by intravenous, once a day.~At the same time, the patients will take domestic riluzole tablets 50mg orally, twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: control group
Description: The patients will take domestic riluzole tablets 50mg orally, twice a day.
Study: NCT01317901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRU-016
Description: 100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab by IV administration at 375 mg/m\^2 on Day 2 of each 28 day cycle.
Study: NCT02198040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational group
Description: * Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.~* Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique.
Study: NCT03220880

Intervention type: DRUG
Intervention: Intranasal dexmedetomidine
Description: Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
Study: NCT03083795

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social relationships intervention
Description: Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
Study: NCT04742868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITH BONE GRAFT
Description: Quadriceps tendon with pattlar bone will used for grating
Study: NCT01660893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3% and oxymetazoline HCl 0.05%
Description: 3 unilateral intranasal sprays per dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracaine HCl 3%
Description: 3 unilateral intranasal sprays per dose
Study: NCT04742868

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH HAMSTRING TENDON GRAFT
Description: Hamstring tendon with will used for grating

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANTERIOR CRUCIATE LIGAMENT RECONSTRUCTION WITH QUADRICEPS TENDON WITHOUT BONE GRAFT
Description: Quadriceps tendon without pattlar bone will used for grating

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: All patients will receive six months rehabilitation program which aim to recover the strength and function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: All patients will receive six months rehabilitation program which aim to recover the strength and function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation protocol
Description: All patients will receive six months rehabilitation program which aim to recover the strength and function
Study: NCT01074320

Intervention type: OTHER
Intervention: Other
Description: Observational study
Study: NCT00545974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: memantine
Description: memantine 10mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: Placebo pill BID
Study: NCT03183661

Intervention type: BIOLOGICAL
Intervention: ALLO-ASC-CD
Description: ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
Study: NCT04460495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arterial Spin Labeling Magnetic Resonance Imaging
Description: Undergo ASL scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pH-Weighted amine CEST
Description: Undergo pH Weighted amine CEST

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oxygen-weighted SAGE-EPI
Description: Undergo Oxygen-weighted SAGE-EPI
Study: NCT02398292

Intervention type: OTHER
Group type: OTHER
Intervention: M3 Program
Description: Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
Study: NCT02442284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ombitasvir/paritaprevir/ritonavir and dasabuvir
Description: Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study: NCT02528149

Intervention type: PROCEDURE
Intervention: tissue of adjacent part and aneurysm of renal aneurysm
Description: the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis

Intervention type: OTHER
Intervention: blood sample
Study: NCT02463500

Intervention type: OTHER
Intervention: DFU
Description: Standard care.
Study: NCT01823575

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone-covered metallic stent
Description: deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double-J stent
Description: Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
Study: NCT04344431

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen treatment (HBOT) i.e. inhalation of pressurized oxygen delivered by a hyperbaric chamber (drug/device)
Description: One session per day of HBOT in addition to the standard treatment with normobaric oxygen
Study: NCT01660893

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 unilateral intranasal sprays per dose
Study: NCT02242838

Intervention type: DRUG
Intervention: Telmisartan
Study: NCT02130596

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-Based Behavioral Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional Counselling
Study: NCT02632188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative routine treatment
Description: Postoperative routine treatment according to the hospitals local routines

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative routine treatment
Description: Postoperative routine treatment according to the hospitals local routines
Study: NCT03359252

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non-stent assisted coiling
Description: non-stent assisted coiling of unruptured intracranial aneurysm
Study: NCT03672565

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-Up Phase: Booster Calls
Description: Upon achieving remission at any remission assessment or completion of remission assessment five, youth will enter the follow-up phase. Youth will receive three weekly 30 minute post-treatment booster phone calls. Calls will focus on homework completion, ERP planning, and relapse prevention skills.
Study: NCT00666640

Intervention type: DEVICE
Intervention: DXA scan of hip
Description: Dual-energy X-ray Absorptiometry scan

Intervention type: DEVICE
Intervention: DXA scan of hip
Description: Dual-energy X-ray Absorptiometry scan
Study: NCT03359252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stent assisted coiling
Description: stent assisted coiling of unruptured intracranial aneurysm
Study: NCT00666640

Intervention type: DEVICE
Intervention: CT scan of hip
Description: Computed Tomography scan

Intervention type: DEVICE
Intervention: CT scan of hip
Description: Computed Tomography scan
Study: NCT01579682

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Therapy (FBT)
Description: 12 sessions of FBT over the course of 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based Therapy with Intensive Family-Focused treatment
Description: FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
Study: NCT03798652

Intervention type: DEVICE
Intervention: Research CMR scan
Description: CMR scanning at a 3Tesla scanner at King's College London

Intervention type: DEVICE
Intervention: Research 3D transthoracic echocardiogram
Description: The scan is required to assess left ventricular systolic function

Intervention type: OTHER
Intervention: 6-minute walk test
Description: Sub maximal exercise that provides a measure for integrated global response of multiple cardiopulmonary and musculoskeletal systems involved in exercise.
Study: NCT03601611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab (RoACTEMRA®)
Description: Prednisolon will be given in case of worsening of symptoms
Study: NCT04098003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: rosuvastatin 20 mg daily or placebo for eight weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo control